在LUAD中,NEDD1过度表达增加了细胞增殖,瘤免疫逃逸和药物耐药性
Ting Zhuo1, Zuotao Wu2, Sirong Chen3
1Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
Journal of Cancer
|April 5, 2024
概括
神经前体细胞表达的下调调节蛋白1 (NEDD1) 促进肺腺癌 (LUAD) 的进展,入侵和转移. NEDD1的升级表明预后不佳,并且与LUAD的免疫逃逸和药物耐药性有关.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 神经前体细胞表达的发育下调调节蛋白1 (NEDD1) 对于线粒分裂和中心体复制至关重要.
- 异常的中心细胞放大和蛋白质表达与非小细胞肺癌转移有关.
- 对于NEDD1在肺腺癌 (LUAD) 进展中的特定作用尚不清楚.
研究的目的:
- 研究NEDD1在肺腺癌 (LUAD) 进展中的作用.
- 评估NEDD1作为LUAD的预后标志物.
- 探索NEDD1与LUAD免疫逃生和耐药性的关联.
主要方法:
- 在泛癌和LUAD患者数据库 (TCGA,GEO) 中分析NEDD1表达.
- 考克斯回归分析以确定预后因素并将其与NEDD1表达相关联.
- 定量PCR (qPCR),免疫组织化学 (IHC) 和siRNA介导的敲除用于LUAD细胞中的功能验证.
- 单细胞分析以确定NEDD1分布及其与免疫逃脱和耐药性的相关性.
主要成果:
- NEDD1在LUAD上调节,促进癌细胞的增殖,迁移,入侵和上皮-介质细胞过渡.
- 过度表达NEDD1显着与LUAD患者的预后不佳有关.
- 在LUAD中,NEDD1上调与增加的免疫逃逸和药物耐药性相关.
结论:
- NEDD1是LUAD的可靠预后生物标志物.
- 过度表达NEDD1有助于LUAD的进展,免疫逃避和治疗耐药性.
- NEDD1代表了对LUAD治疗的潜在新型治疗标.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
10.2K
相关概念视频
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
02:53Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K